Back to today’s briefing

Story perspectives

Intellia Stock Plummets 25% Over Gene Therapy Safety Concerns

5/31/2025

24 3

Summary

Story summary

Intellia Therapeutics faced a staggering 25% drop in stock value after a patient in its gene-editing trial for ATTR cardiomyopathy exhibited signs of liver stress, despite being asymptomatic. This safety concern casts a shadow over ongoing studies, contributing to a troubling 36.1% decline in shares this year, starkly contrasting with the industry’s modest 5.4% dip.

1 of 1

Story summary

Intellia Therapeutics faced a staggering 25% drop in stock value after a patient in its gene-editing trial for ATTR cardiomyopathy exhibited signs of liver stress, despite being asymptomatic. This safety concern casts a shadow over ongoing studies, contributing to a troubling 36.1% decline in shares this year, starkly contrasting with the industry’s modest 5.4% dip.